Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

361 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer.
Drew Y, Ledermann J, Hall G, Rea D, Glasspool R, Highley M, Jayson G, Sludden J, Murray J, Jamieson D, Halford S, Acton G, Backholer Z, Mangano R, Boddy A, Curtin N, Plummer R. Drew Y, et al. Among authors: ledermann j. Br J Cancer. 2016 Mar 29;114(7):723-30. doi: 10.1038/bjc.2016.41. Epub 2016 Mar 22. Br J Cancer. 2016. PMID: 27002934 Free PMC article. Clinical Trial.
Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer.
Drew Y, Ledermann J, Hall G, Rea D, Glasspool R, Highley M, Jayson G, Sludden J, Murray J, Jamieson D, Halford S, Acton G, Backholer Z, Mangano R, Boddy A, Curtin N, Plummer R. Drew Y, et al. Among authors: ledermann j. Br J Cancer. 2016 Jun 14;114(12):e21. doi: 10.1038/bjc.2016.133. Epub 2016 May 26. Br J Cancer. 2016. PMID: 27228289 Free PMC article. No abstract available.
SCOTROC 2B: feasibility of carboplatin followed by docetaxel or docetaxel-irinotecan as first-line therapy for ovarian cancer.
Clamp AR, Mäenpää J, Cruickshank D, Ledermann J, Wilkinson PM, Welch R, Chan S, Vasey P, Sorbe B, Hindley A, Jayson GC; Scottish Gynaecological Cancer Trials Group. Clamp AR, et al. Among authors: ledermann j. Br J Cancer. 2006 Jan 16;94(1):55-61. doi: 10.1038/sj.bjc.6602910. Br J Cancer. 2006. PMID: 16404360 Free PMC article. Clinical Trial.
Improved Survival from Ovarian Cancer in Patients Treated in Phase III Trial Active Cancer Centres in the UK.
Khoja L, Nolan K, Mekki R, Milani A, Mescallado N, Ashcroft L, Hasan J, Edmondson R, Winter-Roach B, Kitchener HC, Mould T, Hutson R, Hall G, Clamp AR, Perren T, Ledermann J, Jayson GC. Khoja L, et al. Among authors: ledermann j. Clin Oncol (R Coll Radiol). 2016 Dec;28(12):760-765. doi: 10.1016/j.clon.2016.06.011. Epub 2016 Jul 9. Clin Oncol (R Coll Radiol). 2016. PMID: 27401967 Free article. Clinical Trial.
Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes.
Hodgson DR, Dougherty BA, Lai Z, Fielding A, Grinsted L, Spencer S, O'Connor MJ, Ho TW, Robertson JD, Lanchbury JS, Timms KM, Gutin A, Orr M, Jones H, Gilks B, Womack C, Gourley C, Ledermann J, Barrett JC. Hodgson DR, et al. Among authors: ledermann j. Br J Cancer. 2018 Nov;119(11):1401-1409. doi: 10.1038/s41416-018-0274-8. Epub 2018 Oct 24. Br J Cancer. 2018. PMID: 30353044 Free PMC article. Clinical Trial.
Targeted anti-vascular therapies for ovarian cancer: current evidence.
Hall M, Gourley C, McNeish I, Ledermann J, Gore M, Jayson G, Perren T, Rustin G, Kaye S. Hall M, et al. Among authors: ledermann j. Br J Cancer. 2013 Feb 5;108(2):250-8. doi: 10.1038/bjc.2012.541. Br J Cancer. 2013. PMID: 23385789 Free PMC article. Review.
An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib.
Mateo J, Moreno V, Gupta A, Kaye SB, Dean E, Middleton MR, Friedlander M, Gourley C, Plummer R, Rustin G, Sessa C, Leunen K, Ledermann J, Swaisland H, Fielding A, Bannister W, Nicum S, Molife LR. Mateo J, et al. Among authors: ledermann j. Target Oncol. 2016 Jun;11(3):401-15. doi: 10.1007/s11523-016-0435-8. Target Oncol. 2016. PMID: 27169564 Free article. Clinical Trial.
Biomarkers and response to bevacizumab--response.
Collinson F, Hutchinson M, Craven RA, Cairns DA, Alexandre Z, Wind TC, Gahir N, Messenger MP, Jackson S, Thompson D, Adusei C, Ledermann J, Hall G, Jayson GC, Selby PJ, Banks RE. Collinson F, et al. Among authors: ledermann j. Clin Cancer Res. 2014 Feb 15;20(4):1058. doi: 10.1158/1078-0432.CCR-13-3269. Clin Cancer Res. 2014. PMID: 24536077 No abstract available.
361 results